These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7087549)

  • 1. Hemosiderosis in a dialysis patient: treatment with hemofiltration and deferoxamine chelation therapy.
    McCarthy JT; Libertin CR; Mitchell JC; Fairbanks VF
    Mayo Clin Proc; 1982 Jul; 57(7):439-41. PubMed ID: 7087549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferoxamine for the treatment of hemosiderosis during CAPD.
    Gomez RA; Campbell F; Savory J; Chevalier RL
    Int J Pediatr Nephrol; 1987; 8(1):21-4. PubMed ID: 3583552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR; Barnett MD; Brozovic B; Cattell WR; Ackrill P; McAlister J; Nimmon C
    Clin Nephrol; 1976 Jul; 6(1):326-8. PubMed ID: 954239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
    Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detoxification in hemosiderosis.
    Simon P
    Blood Purif; 1985; 3(1-3):75-88. PubMed ID: 3913449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hemodialysis hemosiderosis with desferrioxamine.
    Rembold CM; Krumlovsky FA; Roxe DM; Fitzsimmons E; del Greco F
    Trans Am Soc Artif Intern Organs; 1982; 28():621-6. PubMed ID: 7164314
    [No Abstract]   [Full Text] [Related]  

  • 9. Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
    Roxe DM; Krumlovsky FA; Del Greco F; Fitzsimons E
    Int J Artif Organs; 1990 Apr; 13(4):211-7. PubMed ID: 2115505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desferrioxamine in the management of dialysis hemosiderosis.
    Krumlovsky FA
    Int J Artif Organs; 1982 Jul; 5(4):223-5. PubMed ID: 7118282
    [No Abstract]   [Full Text] [Related]  

  • 12. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy and monitoring of hypersiderosis in chronic renal insufficiency.
    Hilfenhaus M; Koch KM; Bechstein PB; Schmidt H; Fassbinder W; Baldamus CA
    Contrib Nephrol; 1984; 38():167-74. PubMed ID: 6713893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
    Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Deferoxamine B treatment of hemosiderosis in the anephric patient undergoing hemodialysis].
    Ceriati F; Cavicchioni C; Marino IR; Pomponi M
    Chir Patol Sper; 1981 Feb; 29(1):14-9. PubMed ID: 7344858
    [No Abstract]   [Full Text] [Related]  

  • 18. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
    Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
    Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ
    Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of hemosiderosis with deferoxamine].
    Strohmeyer G; Stremmel W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1669-70. PubMed ID: 6489179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.